Navigation Links
Spectral announces third quarter 2008 results
Date:11/12/2008

8 and 2007

-------------------------------------------------------------------------

(in thousands of dollars, except share and per share data)

3 Months Ended 9 Months Ended

September 30 September 30

2008 2007 2008 2007

$ $ $ $

Sales 701 739 2,150 2,318

Cost of sales 171 168 560 547

------------------------------------------------

Gross margin 530 571 1,590 1,771

------------------------------------------------

Operating expenses

Selling, general and

administrative 729 799 2,295 2,375

Amortization 160 147 478 433

Foreign exchange (gain)

loss (28) 27 (26) 81

Stock-based compensation 22 - 65 31

Research and product

development, net of tax

credits 4 - 29 (125)

------------------------------------------------

887 973 2,841 2,795

------------------------------------------------

Loss before the following (357) (402) (1,251) (1,024)

Interest expense on

convertible notes payable (41) (41) (123) (124)

Net interest income 66 61 175 180

------------------------------------------------ '/>"/>

SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Spectral to bring anti-sepsis therapy to the U.S. market
2. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
3. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
4. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
5. Spectral and Toray expand collaboration to include new geographic territories
6. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
7. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
8. Spectral announces 2007 financial results
9. Spectral appoints Anthony Bihl to Board of Directors
10. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
11. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... BARCELONA, Spain , April 27, 2015  Together ... during the 3rd ESTRO Forum in Barcelona ... Hope, a nonprofit organization with the mission to improve ... Radiating Hope believes that no patient should ... is not affordable. Consequently, it cooperates with hospitals and ...
(Date:4/24/2015)... 24, 2015 Leading Regenerative Veterinary ... its allogeneic stem-cell product development program and changes ... the corporate strategic direction. , “I am extremely ... stem cell development program has been kicked into ... manufacturing facility and hiring of our new Director ...
(Date:4/24/2015)... , April 24, 2015  Navitas Life Sciences is delighted ... Head of Clinical and Regulatory Services. Shalabh is a proven ... co-founder and CEO of Kinapse, as well as a Strategy ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... commented "I am delighted to welcome Shalabh into this ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
Breaking Biology Technology:Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... Announces Revised Operating Plan to Respond to NEBIDO Delay, ... IDEV ) today announced that it has received,an ... (FDA) for,NEBIDO(R) related to a New Drug Application (NDA) ... on June 27, 2008, indicated that the,application may be ...
... Company to Commercialize ... Novel Technology from UC Davis, BOSTON, ... early stage university business ventures, has,established RF Biocidics, Inc., to ... UC Davis., The newly formed RF Biocidics, Inc. is ...
... 30 Raptor,Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), ... private placement of 20 million units,constituting an aggregate ... and two-year warrants to purchase 10 million shares ... Company raised $9.3 million in,net proceeds from the ...
Cached Biology Technology:Indevus Receives Approvable Letter from FDA for NEBIDO(R) 2Indevus Receives Approvable Letter from FDA for NEBIDO(R) 3Indevus Receives Approvable Letter from FDA for NEBIDO(R) 4Indevus Receives Approvable Letter from FDA for NEBIDO(R) 5Indevus Receives Approvable Letter from FDA for NEBIDO(R) 6Indevus Receives Approvable Letter from FDA for NEBIDO(R) 7Allied Minds Launches Novel Disinfectant/Disinfestant Technology Start-up With UC Davis 2Raptor Pharmaceuticals Closes $10 Million Private Placement 2Raptor Pharmaceuticals Closes $10 Million Private Placement 3Raptor Pharmaceuticals Closes $10 Million Private Placement 4
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... an increasing health problem all over the world. Bacteria ... pharmaceuticals that can combat this threat are in great ... chemical compound in the garlic plant that neutralises resistant ... demonstrates that ajoene the substance present in garlic ...
... as a way to represent the impact of human ... industry over the last two decades. Since the ... it was introduced by researchers William E. Rees and ... a range of complicated phenomena as a single metric, ...
... Mosaic , a new digital publication dedicated to exploring the ... 2014. Mosaic will carry long-form features, articles ... its impact on society. All articles will be free to ... Commons licence so that it can be reproduced and distributed ...
Cached Biology News:Garlic counteracts virulent bacteria 2What good are footprints? 2What good are footprints? 3New digital publication Mosaic explores the science of life 2
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
...
Biology Products: